Romeo Maciuca, Ph.D.

Affiliations: 
2006 University of California, Los Angeles, Los Angeles, CA 
Area:
computer vision; statistical modeling and computing; vision and visual arts; machine learning
Google:
"Romeo Maciuca"

Parents

Sign in to add mentor
Song Chun Zhu grad student 2006 UCLA
 (MCMC analysis: First hitting times, visiting scheme, and auxiliary variables.)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Harris JM, Maciuca R, Bradley MS, et al. (2016) A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. Respiratory Research. 17: 29
Wei X, Kenny JR, Dickmann L, et al. (2015) Assessment of disease related therapeutic protein drug-drug interaction for etrolizumab in patients with moderately to severely active ulcerative colitis. Journal of Clinical Pharmacology
Kalunian KC, Merrill JT, Maciuca R, et al. (2015) A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Annals of the Rheumatic Diseases
Hanania NA, Noonan M, Corren J, et al. (2015) Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 70: 748-56
Kennedy WP, Maciuca R, Wolslegel K, et al. (2015) Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE. Lupus Science & Medicine. 2: e000080
Gauvreau GM, Harris JM, Boulet LP, et al. (2014) Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production. Science Translational Medicine. 6: 243ra85
Mysler EF, Spindler AJ, Guzman R, et al. (2013) Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis and Rheumatism. 65: 2368-79
Rovin BH, Parikh SV, Hebert LA, et al. (2013) Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice? Clinical Journal of the American Society of Nephrology : Cjasn. 8: 147-53
McBride JM, Jiang J, Abbas AR, et al. (2012) Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis and Rheumatism. 64: 3666-76
Rovin BH, Furie R, Latinis K, et al. (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis and Rheumatism. 64: 1215-26
See more...